This study is comprised of 2 parts. Part 1 includes participants with severe renal impairment and normal renal function. Part 2 includes participants with mild and moderate renal impairment and normal renal function. Participants will be residential for a single period of 14 days/13 nights. Participants will be discharged from the clinical unit on day 14 on the condition that all required assessments have been performed and that there are no medical reasons for a longer stay in the clinical unit.
The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of gilteritinib in male and female participants with severe, mild and moderate renal impairment compared to healthy male and female participants with normal renal function. This study will also evaluate the safety and tolerability of a single oral dose of gilteritinib in male and female participants with severe, mild and moderate renal impairment and healthy male and female participants with normal renal function.